<DOC>
	<DOC>NCT02137954</DOC>
	<brief_summary>This is a multicenter, prospective, randomized, placebo-controlled, double-blind, two-parallel groups study comparing lidocaine (experimental group) to placebo (control group). The study protocol was elaborated using the recommendations of the Consolidated Standards of Reporting Trials (CONSORT) Statement.</brief_summary>
	<brief_title>Efficacy of Lidocaine Versus Placebo in Palliative Care Patients With Opioid-refractory Cancer Pain With Neuropathic Component: a Multicenter, Prospective, Double-blind Randomized Placebo-controlled Study.</brief_title>
	<detailed_description />
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Patient aged 18 years or older Patient suffering from cancer pain refractory to standard opiates (numeric pain intensity scale NPIS &gt;=4/10 after 24 hours of continuous intravenous morphine or oxycodone administration [SOR 2002, analgesics drugs for adults cancer nociceptive pain]), regardless of the nature of the primary cancer] Patient suffering from cancer neuropathic or mixed pain (DNA survey score&gt; = 4 [Bouhassira 2004]) Patient receiving palliative care as defined by French Society of Palliative and Support Care [Charte des Soins Palliatifs, 1996, Act No. 99477 of 9 June 1999 to guarantee the right of access to palliative care] according to the definition of the World Health Organization (WHO) [World Health Organization. WHO's pain ladder. http://www.who.int/cancer/palliative/painladder/en/. Accessed December 9.2011] Patient with histological diagnosis of cancer, locally advanced or metastatic disease Patient without curative cancer treatment, and with or without palliative anticancer treatment Patient hospitalized in a specific palliative care unit Patient with an estimated survival higher than 48 hours (physician estimation) Patient providing written informed consent for participation prior to any study procedures. Patient with a known hypersensitivity to lidocaine Patient with a history of porphyria, arrhythmias, disorders of atrioventricular conduction requiring permanent pacing not yet realized, uncontrolled epilepsy, uncontrolled hypertension Patient with hematologic malignancy, abnormal renal, hepatic and cardiac functions Patient with a altered sleepiness (Epworth scale score ≤ 16) Patient with altered cognitive function (TELECOM scale score&gt; 11) [Arsène 2000] Patient not native French speaker Patient defined as vulnerable subject (minor subject, pregnant or nursing woman, subject freedom deprived)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>cancer</keyword>
	<keyword>pain</keyword>
</DOC>